Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Approves Supplemental Application for Methadone Hydrochloride Intensol by Hikma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Hikma18 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/29/2026, 6:32:46 AM

Assessment confidence: 55% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of Hikma's supplemental application for Methadone Hydrochloride Intensol is significant as it strengthens Hikma's position in the competitive opioid market. This could lead to shifts in market dynamics and necessitate strategic responses from other manufacturers in the pain management sector. Regulatory context from FDA (FDA AP — METHADONE HYDROCHLORIDE INTENSOL (SUPPL)) supports the near-term read. Assessment grounded in 10 ranked evidence items (3 high-relevance).

Strategic Assessment

The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 4 regulatory and 2 competitive items passed relevance filtering for Hikma. Hikma's enhanced product offering may capture additional market share in the opioid segment, impacting revenue streams for competitors.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This approval may enhance Hikma's position in the pain management market, particularly in the opioid segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — METHADONE HYDROCHLORIDE INTENSOL (SUPPL) (FDA). Entity match (hikma). The approval indicates compliance with FDA standards, which could influence future submissions and regulatory strategies for similar products.

Key Risks

Elevated medium regulatory exposure for Hikma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Hikma's enhanced product offering may capture additional market share in the opioid segment, impacting revenue streams for competitors.
The implications of this approval on Hikma's competitive stance and potential market share in opioid therapies.

What Would Change This Assessment

This becomes more urgent if Monitor for market uptake and any subsequent competitive responses from other opioid manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — METHADONE HYDROCHLORIDE INTENSOL (SUPPL)
FDAmedium relevance
Entity match (hikma)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hikma)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hikma)
FDA document
View source
FDA AP — SOLRIAMFETOL HYDROCHLORIDE (ORIG)
FDAmedium relevance
Entity match (hikma)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hikma
Methadone Hydrochloride Intensol

Commercial impact

medium

Hikma's enhanced product offering may capture additional market share in the opioid segment, impacting revenue streams for competitors.

Regulatory impact

medium

The approval indicates compliance with FDA standards, which could influence future submissions and regulatory strategies for similar products.

What to watch

Monitor for market uptake and any subsequent competitive responses from other opioid manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.